Hybrid immunity from SARS-CoV-2 infection and mRNA BNT162b2 vaccine among Thai school-aged children
Objective: To compare the immune response of hybrid immunity – arising from SARS-CoV-2 infection and mRNA BNT162b2 vaccination – to that of 2-doses of vaccine. Methods: In a subanalysis of BNT162b2 vaccine trial in 5 to 11-year-old children, There were 179 children who had hybrid immunity compared w...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-12-01
|
| Series: | Vaccine: X |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590136223001559 |
| _version_ | 1797388658635964416 |
|---|---|
| author | Kanchanok Saraban Piyarat Suntarattiwong Napaporn Chantasrisawad Sophida Boonsathorn Pope Kosalaraksa Wanatpreeya Phongsamart Auchara Tangsathapornpong Peera Jaruampornpan Suchada Srisarang Thanyawee Puthanakit |
| author_facet | Kanchanok Saraban Piyarat Suntarattiwong Napaporn Chantasrisawad Sophida Boonsathorn Pope Kosalaraksa Wanatpreeya Phongsamart Auchara Tangsathapornpong Peera Jaruampornpan Suchada Srisarang Thanyawee Puthanakit |
| author_sort | Kanchanok Saraban |
| collection | DOAJ |
| description | Objective: To compare the immune response of hybrid immunity – arising from SARS-CoV-2 infection and mRNA BNT162b2 vaccination – to that of 2-doses of vaccine. Methods: In a subanalysis of BNT162b2 vaccine trial in 5 to 11-year-old children, There were 179 children who had hybrid immunity compared with 134 children with solely 2-dose vaccine. The immunological outcome was a surrogate virus neutralization test (sVNT) against the Omicron strain, BA.1, (%inhibition). An sVNT level ≥68 % inhibition was considered as protective immune response. Results: From February to April 2022, 179 children had COVID-19 natural infection resulting in hybrid immunity included: Group1;prior vaccination(n = 17), Group2;after the first dose(n = 61), and Group3;after the second dose(n = 97). The proportion of children with protective immune response was higher in Group 3 and Group 1 – 61.9 % and 58.8 %, compared to 36.1 % and 34.3 % in Group 2 and comparator group (2 doses of vaccine), respectively. The geometric mean % inhibition of sVNT was higher in Group 1 (68.5, 95 %CI 55.5–84.6) and Group 3 (63.5, 95 %CI 55.5–72.6), followed by comparator group (49.6, 95 %CI 44.8–54.9) and Group 2 (42.1, 95 %CI 34.6–51.3), p < 0.001. Conclusions: Immune response that arises from BNT162b2 vaccine after natural infection and infection after 2 doses of BNT162b2 was higher than infection after partially-vaccinated children. |
| first_indexed | 2024-03-08T22:44:00Z |
| format | Article |
| id | doaj.art-1787c343a98041f499cbf437a0b8d7de |
| institution | Directory Open Access Journal |
| issn | 2590-1362 |
| language | English |
| last_indexed | 2024-03-08T22:44:00Z |
| publishDate | 2023-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Vaccine: X |
| spelling | doaj.art-1787c343a98041f499cbf437a0b8d7de2023-12-17T06:41:39ZengElsevierVaccine: X2590-13622023-12-0115100414Hybrid immunity from SARS-CoV-2 infection and mRNA BNT162b2 vaccine among Thai school-aged childrenKanchanok Saraban0Piyarat Suntarattiwong1Napaporn Chantasrisawad2Sophida Boonsathorn3Pope Kosalaraksa4Wanatpreeya Phongsamart5Auchara Tangsathapornpong6Peera Jaruampornpan7Suchada Srisarang8Thanyawee Puthanakit9Queen Sirikit National Institute of Child Health, Bangkok, Thailand; Corresponding author at: Division of Infectious Diseases, Queen Sirikit National Institute of Child Health, Department of Medical Services, Ministry of Public Health, 420/8 Rajavithi Road, Rajatevee, Bangkok 14000, Thailand.Queen Sirikit National Institute of Child Health, Bangkok, ThailandDepartment of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Thai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial Hospital, Bangkok, ThailandDepartment of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, ThailandPediatric Infectious Disease Unit, Faculty of Medicine, Khon Kaen University, Khon Kaen, ThailandDivision of Infectious Diseases, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandDivision of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani, ThailandVirology and Cell Technology Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani, ThailandQueen Sirikit National Institute of Child Health, Bangkok, ThailandDepartment of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn University, Bangkok, ThailandObjective: To compare the immune response of hybrid immunity – arising from SARS-CoV-2 infection and mRNA BNT162b2 vaccination – to that of 2-doses of vaccine. Methods: In a subanalysis of BNT162b2 vaccine trial in 5 to 11-year-old children, There were 179 children who had hybrid immunity compared with 134 children with solely 2-dose vaccine. The immunological outcome was a surrogate virus neutralization test (sVNT) against the Omicron strain, BA.1, (%inhibition). An sVNT level ≥68 % inhibition was considered as protective immune response. Results: From February to April 2022, 179 children had COVID-19 natural infection resulting in hybrid immunity included: Group1;prior vaccination(n = 17), Group2;after the first dose(n = 61), and Group3;after the second dose(n = 97). The proportion of children with protective immune response was higher in Group 3 and Group 1 – 61.9 % and 58.8 %, compared to 36.1 % and 34.3 % in Group 2 and comparator group (2 doses of vaccine), respectively. The geometric mean % inhibition of sVNT was higher in Group 1 (68.5, 95 %CI 55.5–84.6) and Group 3 (63.5, 95 %CI 55.5–72.6), followed by comparator group (49.6, 95 %CI 44.8–54.9) and Group 2 (42.1, 95 %CI 34.6–51.3), p < 0.001. Conclusions: Immune response that arises from BNT162b2 vaccine after natural infection and infection after 2 doses of BNT162b2 was higher than infection after partially-vaccinated children.http://www.sciencedirect.com/science/article/pii/S2590136223001559Hybrid immunitySARS-CoV-2Omicron variantBNT162b2Neutralizing antibodySchool-aged children |
| spellingShingle | Kanchanok Saraban Piyarat Suntarattiwong Napaporn Chantasrisawad Sophida Boonsathorn Pope Kosalaraksa Wanatpreeya Phongsamart Auchara Tangsathapornpong Peera Jaruampornpan Suchada Srisarang Thanyawee Puthanakit Hybrid immunity from SARS-CoV-2 infection and mRNA BNT162b2 vaccine among Thai school-aged children Vaccine: X Hybrid immunity SARS-CoV-2 Omicron variant BNT162b2 Neutralizing antibody School-aged children |
| title | Hybrid immunity from SARS-CoV-2 infection and mRNA BNT162b2 vaccine among Thai school-aged children |
| title_full | Hybrid immunity from SARS-CoV-2 infection and mRNA BNT162b2 vaccine among Thai school-aged children |
| title_fullStr | Hybrid immunity from SARS-CoV-2 infection and mRNA BNT162b2 vaccine among Thai school-aged children |
| title_full_unstemmed | Hybrid immunity from SARS-CoV-2 infection and mRNA BNT162b2 vaccine among Thai school-aged children |
| title_short | Hybrid immunity from SARS-CoV-2 infection and mRNA BNT162b2 vaccine among Thai school-aged children |
| title_sort | hybrid immunity from sars cov 2 infection and mrna bnt162b2 vaccine among thai school aged children |
| topic | Hybrid immunity SARS-CoV-2 Omicron variant BNT162b2 Neutralizing antibody School-aged children |
| url | http://www.sciencedirect.com/science/article/pii/S2590136223001559 |
| work_keys_str_mv | AT kanchanoksaraban hybridimmunityfromsarscov2infectionandmrnabnt162b2vaccineamongthaischoolagedchildren AT piyaratsuntarattiwong hybridimmunityfromsarscov2infectionandmrnabnt162b2vaccineamongthaischoolagedchildren AT napapornchantasrisawad hybridimmunityfromsarscov2infectionandmrnabnt162b2vaccineamongthaischoolagedchildren AT sophidaboonsathorn hybridimmunityfromsarscov2infectionandmrnabnt162b2vaccineamongthaischoolagedchildren AT popekosalaraksa hybridimmunityfromsarscov2infectionandmrnabnt162b2vaccineamongthaischoolagedchildren AT wanatpreeyaphongsamart hybridimmunityfromsarscov2infectionandmrnabnt162b2vaccineamongthaischoolagedchildren AT aucharatangsathapornpong hybridimmunityfromsarscov2infectionandmrnabnt162b2vaccineamongthaischoolagedchildren AT peerajaruampornpan hybridimmunityfromsarscov2infectionandmrnabnt162b2vaccineamongthaischoolagedchildren AT suchadasrisarang hybridimmunityfromsarscov2infectionandmrnabnt162b2vaccineamongthaischoolagedchildren AT thanyaweeputhanakit hybridimmunityfromsarscov2infectionandmrnabnt162b2vaccineamongthaischoolagedchildren |